Mol Ther Oncol

Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement.

Fletcher EAK, Cordfunke RA, Nasi A, ..., Drijfhout JW, Mangsbo SM

Mol Ther Oncol 33 (2) 200954 [2025-06-18; online 2025-02-20]

Molecular and functional profiling of primary normal ovarian cells defines insights into cancer development and drug responses.

Piki E, Dini A, Rantanen F, ..., Murumägi A, Ungureanu D

Mol Ther Oncol 32 (4) 200903 [2024-12-19; online 2024-11-08]